Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

NCT04333914 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV-2 (COVID-19) Infection
Advanced or Metastatic Hematological or Solid Tumor

Interventions

DRUG: Autophagy inhibitor (GNS651)
OTHER: Standard of care
DRUG: Avdoralimab
DRUG: Monalizumab

Sponsor

Centre Leon Berard